What Retabolil Treats: Main Uses and Benefits

This medication is generally applied across therapeutic domains involving deficiencies in blood cell count and severe tissue loss, and may be part of supportive management in chronic catabolic states. The medication is applied across conditions such as anemia of chronic kidney insufficiency, pathological bone loss (osteoporosis), and wasting syndromes that cause debilitating physical decline.

The medication helps manage symptom clusters that create noticeable physiological strain, primarily severe muscle weakness and bone fragility. It may assist with maintaining functional stability and supports the process of tissue repair in patients with chronic debilitating illnesses, helping them cope more steadily with symptom fluctuations.

---

Quick Fact: Relief for Systemic Wasting

Retabolil is commonly applied in clinical settings that involve heightened systemic burden, including scenarios requiring significant convalescence, such as after severe trauma or surgery. It contributes to easing the overall symptom load by supporting bone health and the process of tissue repair, which helps support general well-being when conditions produce significant symptomatic burden.

Regulatory References

1. DailyMed official information on Nandrolone Decanoate

Official Eligibility and Contraindications

Retabolil (nandrolone decanoate) is an anabolic steroid whose use is strictly governed by medical necessity and several formal restrictions. Its eligibility is defined by the absence of specific health conditions, physiological states, and age considerations.

Classification	Populations Who Must Not Use (Contraindicated)
Hormone-Sensitive	Men with prostate carcinoma or breast carcinoma (known or suspected). Women with breast cancer and hypercalcemia (high calcium levels).
Physiological State	Women who are pregnant or at risk of becoming pregnant. Women who are breast-feeding.
Organ Dysfunction	Patients with nephrosis or the nephrotic phase of nephritis (severe kidney disease), or cardio-renal failure. Patients with liver disease and impaired bilirubin excretion (severe hepatic impairment).
Allergy	Patients with a known hypersensitivity to nandrolone decanoate, other anabolic steroids, or excipients (e.g., peanut oil).

Restricted or Special Consideration Populations

• Children: Use is generally not recommended; when used, it requires extreme caution and regular X-ray monitoring of bone age to prevent premature closure of the epiphyses and compromised adult height.
• Elderly: Requires careful monitoring, especially for potential prostate enlargement and changes in lipid profile.
• Existing Conditions: Patients with pre-existing cardiac, renal, or hepatic disease (not severe enough to be contraindicated), diabetes, epilepsy, or migraine require great caution due to the risk of fluid retention and other complications. Female patients must be monitored for signs of virilization (masculinizing effects).

The interaction profile of Retabolil (Nandrolone Decanoate) is established by documented pharmacodynamic changes and metabolic clearance factors described in official regulatory information.

Category	Interacting Substances/Factors	Official Interaction Outcome
Anticoagulants	Warfarin-type medicines	Increases anticoagulant effect, raising Prothrombin Time (PT) and International Normalized Ratio (INR).
Antidiabetic Agents	Insulin, Oral Hypoglycemics	Improves glucose tolerance, potentially decreasing the requirement for these agents.
Adrenal Steroids	Corticosteroids, ACTH	Risk of additive edema formation (fluid retention).
Metabolic Clearance	Hepatic Enzyme Inducers (e.g., Rifampicin, Phenytoin)	May decrease the therapeutic effectiveness of Retabolil.
Restrictions	Heparin	Concomitant use should be avoided.
Contraindication	Peanuts or Soya (Excipients)	Contraindicated due to risk of hypersensitivity.

The product's regulatory profile highlights pharmacodynamic enhancement with several substance classes. Co-administration with anticoagulants requires attention due to heightened effects on blood clotting. In diabetic patients, improved glucose tolerance can alter the needs for antidiabetic medicines. Separately, the clearance rate of Retabolil is subject to alteration by hepatic enzyme inducers, including specific anticonvulsants, which may lead to reduced overall efficacy. Furthermore, the official labeling imposes formal restrictions, requiring the avoidance of Heparin and establishing an excipient-related contraindication for individuals with known allergies to peanuts or soya.

How Retabolil Works

Retabolil is the trade name for nandrolone decanoate. Its primary biological target is the androgen receptor (AR), a ligand-activated transcription factor found predominantly in skeletal muscle and bone tissue cells. Upon administration, the drug's decanoate ester is cleaved to release the active molecule, nandrolone, which enters target cells.

Nandrolone acts as an agonist, binding directly to the intracellular androgen receptor with high affinity. This specific interaction induces a conformational change in the receptor. The resulting drug-receptor complex then translocates from the cytoplasm into the cell nucleus. Within the nucleus, the complex interacts with specific DNA response elements, leading to the enhanced transcription of genes that encode structural and enzymatic proteins. This mechanistic cascade drives increased protein synthesis and diminished protein breakdown.

At the system-level, this modulation of anabolic and catabolic pathways establishes a positive nitrogen balance in the body. This physiological consequence promotes tissue generation in muscle and bone cells.

Administration of Retabolil (Nandrolone Decanoate)

The administration of Retabolil, which contains the active ingredient nandrolone decanoate, follows specific procedural steps for its therapeutic applications. The drug is for parenteral use, delivered by deep intramuscular injection.

Administration Scope	Instruction
Route of administration	Deep intramuscular injection only, preferably into the gluteal muscle.
Preparation requirements	Parenteral drug products must be inspected visually for particulate matter and discoloration prior to administration, whenever the solution and container permit.
Special procedural conditions	Therapy should be intermittent if possible. It is considered adjunctive therapy, requiring adequate intake of nutrients (e.g., iron for refractory anemia) to achieve maximal effects.

Dosing Schedule

The frequency and dosage are determined by the treating physician based on the specific condition and the patient's response. The following parameters relate to the management of anemia of renal insufficiency:

Age Group	Frequency Pattern	Dosing Range
Adult Men	Weekly	100 to 200 mg per week
Adult Women	Weekly	50 to 100 mg per week
Children (2 to 13 years)	Every 3 to 4 weeks	25 to 50 mg every 3 to 4 weeks

Missed-dose Rules: Drug therapy is discontinued if no hematologic improvement is observed within the first six months of treatment. There are no general instructions for the procedure of a missed dose in available documentation.

Research evidence / Overview of studies for Retabolil

---

Evidence for Use in Pathological Bone Loss (Osteoporosis)

Research exploring the use of Retabolil for pathological bone loss primarily involved Randomized Controlled Trials (RCTs) and Systematic Reviews. These studies focused on populations of elderly postmenopausal women and examined outcomes such as measured changes in Bone Mineral Density (BMD) at the hip and spine, and tracked new vertebral fractures. Studies reported patterns of change in BMD and monitored changes in Lean Body Mass (LBM) measurements. However, the certainty of the evidence for certain outcomes remains moderate to low, and long-term outcomes concerning the persistence of these measured changes after two years are not fully established.

---

Evidence for Use in Wasting Syndromes and Severe Tissue Loss

The evidence base for severe tissue loss, such as HIV-associated wasting syndrome, includes short-term, placebo-controlled trials that explored changes in body composition. These studies monitored outcomes like absolute changes in LBM and Fat-Free Mass in adult men and women. Trials reported patterns of change in body composition, with data showing a measured shift in LBM in the observed populations. A key gap is that existing trials are generally limited in size and duration, which means that long-term outcomes are not fully established, and studies provide limited insight beyond physical composition changes.

---

Foundational Evidence for Anemia of Chronic Kidney Insufficiency

The initial regulatory basis for Retabolil's use in anemia stems from controlled clinical trials conducted historically. These foundational studies monitored changes in blood cell parameters, specifically measuring Hemoglobin (Hb) levels and Hematocrit (HCT) values. Clinical trials described patterns involving increases in measured Hb and HCT over a period of several months. Due to its historical nature, the current research base has limited comparative evidence against modern standard-of-care treatments for this type of anemia.

---

Research Gaps and Areas of Uncertainty

The overall evidence landscape highlights several research gaps. The evidence level is low for the broad indication of general chronic catabolic states due to a lack of robust, contemporary controlled trials. In multiple indications, the sample sizes were modest, and follow-up durations were limited, resulting in findings that describe group patterns, not personal outcomes. Furthermore, the studies often rely on biomarkers related to metabolic changes rather than defined major clinical endpoints.

Key Studies & References Nandrolone Decanoate Injection - DailyMed (Official Prescribing Information)

Common questions about Retabolil (FAQ)

Q: How often is the Retabolil injection typically administered?

The frequency of administration is determined by a healthcare provider's assessment based on the patient's specific condition. Regulatory guidelines indicate that for the management of anemia of renal insufficiency, the dosing pattern is often administered weekly for adults. For children (ages 2 to 13), the injection is generally administered every three to four weeks.

Q: Does Retabolil cause fluid retention?

Official product information lists fluid retention, or edema, as a commonly reported side effect associated with the use of this medicine. The risk of fluid retention may also be increased when this medicine is used concomitantly with certain adrenal corticosteroid medicines.

Q: Is Retabolil a testosterone replacement drug?

Retabolil contains the active ingredient Nandrolone Decanoate, which is classified as an Anabolic Androgenic Steroid (AAS) and is a synthetic derivative of testosterone. The compound's primary role is supporting tissue building (anabolism). Regulatory documents do not classify or prescribe it as a testosterone replacement therapy.

Q: Can Retabolil be used by patients who have diabetes?

Patients with pre-existing diabetes require special caution and close monitoring while using this medication. Official information states that Retabolil can potentially improve glucose tolerance. This can alter the requirements for anti-diabetic medications, such as insulin or oral hypoglycemic agents, requiring professional adjustment.

Q: How quickly does Retabolil start to work for anemia?

The official guidelines for the use of Retabolil in anemia of renal insufficiency do not suggest an immediate therapeutic effect. The official product labeling indicates that therapy should be discontinued if no hematologic improvement is noted within the first six months of treatment. This suggests the effects are assessed over an extended period.

Q: What is the difference between Retabolil and Deca-Durabolin?

Regulatory records indicate that Retabolil and Deca-Durabolin are different trade names for the exact same chemical substance. Both products share the same active ingredient, which is Nandrolone Decanoate injection, with the same approved uses.

How to Store and Dispose of Retabolil

Retabolil (Nandrolone Decanoate injection) requires strict adherence to official storage and handling guidelines to maintain product stability.

Storage Requirements

The medicine must be stored at a controlled room temperature, typically between 20 C to 25 C or below 25 C, depending on the formulation's labeling. It is a mandatory requirement that the product must not be refrigerated. To protect the oily solution from light, the vial or ampoule must be stored in its original outer carton. Any single-dose ampoules must be used immediately after opening. As with all medications, Retabolil must be stored out of the sight and reach of children.

Disposal

Any unused or expired product, along with any related waste materials, must be handled and disposed of in accordance with local regulatory requirements. This instruction prevents improper disposal into household waste or wastewater.